Skip to content

Analgesic Effect of Intravenous Lidocaine in Femoral Fractures

Comparison of Venous Infusion of Lidocaine and Intravenous Injection of Pethidine for the Management of Acute Pain Due to Femoral Fractures

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20231213060355N1
Enrollment
72
Registered
2023-12-30
Start date
2024-01-05
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Femoral bone fracture. Fracture of femur

Interventions

Intervention 1: Intervention group: Intravenous infusion of lidocaine (3 mg/kg during 20 minutes, Maximum dose 200 mg). Intervention 2: Control group: Intravenous pethidine (25 mg).

Sponsors

Artesh University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age >= 18 years-old Femoral bone fracture Severe pain based on numerical rating scale of pain (NRS) (NRS>=7)

Exclusion criteria

Exclusion criteria: Age > 70 years-old Crush injury of limb and open fractures Acute diseases except of fractures Pregnancy Presence or history of cardiac block or bradycardia Presence or history of seizure Neuromuscular diseases Neuropathic disease Diabetes History of consumption of analgesic or anti-inflammatory drugs History of opioids consumption Allergic history of lidocaine and pethidine

Design outcomes

Primary

MeasureTime frame
Numerical Rating Scale of Pain. Timepoint: Before drug administration, 10, 20, 30, 40, 50, 60 minutes after drug administration. Method of measurement: Visual Analogue Scale (VAS) for Pain.

Secondary

MeasureTime frame
Drug adverse events. Timepoint: During the 4 hours after drug administration. Method of measurement: Vital sign monitoring and evaluating the signs and symptoms.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrshad Namazi

Artesh University of Medical Sciences

dr.m.namazi@ajaums.ac.ir+98 21 8609 6350

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026